Australian Clinical Labs Limited

ASX:ACL Stock Report

Mkt Cap: AU$610.5m

We’ve recently updated our valuation analysis.

Australian Clinical Labs Valuation

Is ACL undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

6/6

Valuation Score 6/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACL?

Other financial metrics that can be useful for relative valuation.

ACL key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.8x
Enterprise Value/EBITDA3x
PEG Ratio-0.06x

Price to Earnings Ratio vs Peers

How does ACL's PE Ratio compare to its peers?

The above table shows the PE ratio for ACL vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average26.1x
IDX Integral Diagnostics
51.8x23.0%AU$759.4m
CAJ Capitol Health
31.7x21.3%AU$335.0m
HLS Healius
6.2x-24.1%AU$1.8b
SLA SILK Laser Australia
14.5x21.0%AU$94.0m
ACL Australian Clinical Labs
3.5x-53.3%AU$610.5m

Price-To-Earnings vs Peers: ACL is good value based on its Price-To-Earnings Ratio (3.5x) compared to the peer average (26.1x).


Price to Earnings Ratio vs Industry

How does ACL's PE Ratio compare vs other companies in the Global Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a4.9%
n/an/an/a

Price-To-Earnings vs Industry: ACL is good value based on its Price-To-Earnings Ratio (3.5x) compared to the Global Healthcare industry average (19.1x)


Price to Earnings Ratio vs Fair Ratio

What is ACL's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACL PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio3.5x
Fair PE Ratio5.9x

Price-To-Earnings vs Fair Ratio: ACL is good value based on its Price-To-Earnings Ratio (3.5x) compared to the estimated Fair Price-To-Earnings Ratio (5.9x).


Share Price vs Fair Value

What is the Fair Price of ACL when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: ACL (A$3.07) is trading below our estimate of fair value (A$12.32)

Significantly Below Fair Value: ACL is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACL forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentAU$3.07
AU$4.11
+33.8%
13.5%AU$4.70AU$3.30n/a6
Jan ’24AU$2.98
AU$4.27
+43.3%
7.0%AU$4.70AU$3.83n/a6
Dec ’23AU$3.36
AU$4.62
+37.5%
16.7%AU$5.70AU$3.83n/a6
Nov ’23AU$3.49
AU$4.62
+32.4%
16.7%AU$5.70AU$3.83n/a6
Oct ’23AU$3.53
AU$4.89
+38.6%
14.0%AU$5.70AU$4.10n/a6
Sep ’23AU$4.28
AU$5.10
+19.2%
11.8%AU$5.70AU$4.10n/a6
Aug ’23AU$5.18
AU$5.78
+11.6%
11.7%AU$6.50AU$4.50n/a5
Jul ’23AU$4.50
AU$5.99
+33.1%
9.2%AU$6.50AU$5.00n/a5
Jun ’23AU$5.43
AU$5.99
+10.3%
9.0%AU$6.50AU$5.00n/a5
May ’23AU$5.15
AU$5.80
+12.6%
11.4%AU$6.50AU$5.00n/a4
Apr ’23AU$5.08
AU$5.80
+14.2%
11.4%AU$6.50AU$5.00n/a4
Mar ’23AU$4.70
AU$5.80
+23.4%
11.4%AU$6.50AU$5.00n/a4
Feb ’23AU$5.07
AU$5.95
+17.4%
10.3%AU$6.60AU$5.20n/a4
Jan ’23AU$6.20
AU$5.77
-7.0%
10.4%AU$6.60AU$5.20AU$2.983
Dec ’22AU$4.30
AU$5.47
+27.1%
5.7%AU$5.90AU$5.20AU$3.363
Nov ’22AU$4.36
AU$5.37
+23.1%
7.2%AU$5.90AU$5.00AU$3.493
Oct ’22AU$4.52
AU$5.12
+13.2%
10.0%AU$5.70AU$4.45AU$3.533
Sep ’22AU$4.40
AU$4.98
+13.3%
8.6%AU$5.50AU$4.45AU$4.283
Aug ’22AU$3.88
AU$4.47
+15.1%
11.9%AU$5.10AU$3.80AU$5.183
Jul ’22AU$3.49
AU$4.65
+33.2%
3.2%AU$4.80AU$4.50AU$4.502

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies